Imaging surveillance in multiple endocrine neoplasia type 1 – 10 years of experience with somatostatin receptor positron emission tomography

#3634

Introduction: Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive imaging surveillance without specifying a superior regimen, including the role of somatostatin receptor imaging (SRI) with positron emission tomography (PET).

Aim(s): 1) Assess change in treatment of duodenal-pancreatic neuroendocrine neoplasms (DP-NENs), bronchopulmonary NENs and thymic tumors attributed to use of SRI PET/Computed tomography (CT), 2) Estimate exposure and risk of cancer death attributed to imaging radiation, 3) Investigate the number of DP-NENs detected with CT vs. magnetic resonance imaging (MRI) vs. SRI PET.

Materials and methods: Retrospective single center study, including all MEN1 patients, who had had at least one SRI PET/CT.

Conference:

Presenting Author: Andreassen M

Authors: Said M, Krogh J, Feldt-Rasmussen U, Rasmussen �, Kristensen T,

Keywords: Imaging, Multiple endocrine neoplasia type 1, Neuroendocrine neoplasm, Positron emission tomography, Somatostatin receptor,